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Abstract
BACKGROUND
There is a growing evidence regarding an increased risk of inflammatory bowel
disease (IBD) among patients with airway diseases.
AIM
To investigate the influence of chronic obstructive pulmonary disease (COPD) on
the risk of IBD.
METHODS
A nationwide, population-based study was conducted using data from the
National Health Insurance Service database. A total of 1303021 patients with
COPD and 6515105 non-COPD controls were identified. The COPD group was
divided into the severe and the mild COPD group according to diagnostic
criteria. The risk of IBD in patients with COPD compared to controls was
analyzed by Cox proportional hazard regression models. The cumulative
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incidences of IBD were compared between the groups.
RESULTS
The COPD group had higher incidences of IBD compared to non-COPD controls
(incidence rate, 9.98 vs 7.18 per 100000 person-years, P < 0.001). The risk of IBD in
the COPD group was increased by 1.38 (adjusted hazard ratio (HR); 95%CI: 1.25-
1.52). The incidence rate of IBD was higher in the severe COPD group than in the
mild COPD group (12.39 vs 9.77 per 100000 person-year, P < 0.001). The severity
of COPD was associated with an increased risk of IBD (adjusted HR 1.70 in
severe COPD, 95%CI: 1.27-2.21 and adjusted HR 1.35 in mild COPD, 95%CI: 1.22-
1.49)
CONCLUSION
The incidences of IBD were significantly increased in COPD patients in South
Korea and the risk of developing IBD also increased as the severity of COPD
increased.
Key words: Claim data; Inflammatory bowel disease; Chronic obstructive pulmonary
disease; Crohn’s disease; Ulcerative colitis
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Core tip: In this nationwide population-based study, we showed that the incidence of
inflammatory bowel disease (IBD) was higher in chronic obstructive pulmonary disease
(COPD) patients compared to age-and sex-matched controls without IBD in South
Korea. And the risk of developing IBD also increased as the severity of COPD
increased. It is important to be aware of the gastrointestinal symptoms indicative of IBD
in COPD patients. Accurate clinical assessment should be done, especially in patients
with severe COPD in order to prevent complications and avoid excess medical expenses.
Citation: Lee J, Im JP, Han K, Park S, Soh H, Choi K, Kim J, Chun J, Kim JS. Risk of
inflammatory bowel disease in patients with chronic obstructive pulmonary disease: A
nationwide, population-based study. World J Gastroenterol 2019; 25(42): 6354-6364
URL: https://www.wjgnet.com/1007-9327/full/v25/i42/6354.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i42.6354
INTRODUCTION
Inflammatory bowel disease (IBD), which is divided into Crohn’s disease (CD) and
ulcerative colitis (UC), is a chronic idiopathic disorder causing inflammation of the
gastrointestinal tract. However, IBD should be regarded as a systemic disorder not
limited to the gastrointestinal tract because extraintestinal manifestations of IBD are
frequent and may occur before or after IBD diagnosis[1]. Extraintestinal manifestation
frequently affect joints, skin, hepatobiliary tract and eye. Although the lung is less
affected than other organ, IBD is known to be associated with a variety of lung disease
and airway disease is the most common respiratory manifestation in IBD patients[2-5].
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible
airflow  limitation,  which  is  caused  by  chronic  airway  inflammation  and  lung
parenchymal destruction. It is well-known that not only respiratory symptoms but
also extra-pulmonary manifestations such as cardiovascular compromise, dysfunction
of  skeletal  muscles,  osteoporosis,  and anemia  can  result  in  impaired  functional
capacity  and  increased  mortality  in  COPD  patients.  The  gastrointestinal
manifestations are no exception to this, and a recent report showed that complaints of
gastrointestinal symptoms may be higher in patients with COPD than in healthy
individuals[6]. Furthermore, the associations of COPD with specific gastrointestinal
disease were investigated. And there is a growing evidence regarding an increased
risk of IBD incidence among patients with airway diseases including COPD[7-10].
South Korea has a considerably higher prevalence of COPD than other countries,
with 15.5/1000 people diagnosed with COPD annually[11,12]. Meanwhile, the incidence
of IBD in South Korea has increased approximately 10-fold over the last two decades,
which has led to South Korea having one of the highest incidence of IBD among Asian
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countries[13-16].  These trends of incidence and prevalence may lead to considerable
economic burdens and challenge for the healthcare system. Asian IBD is known to be
different  from  that  of  the  Western  countries  in  s  pathophysiology,  clinical
manifestation and response to treatment[17-19].
Thus, in the present study, we aimed to investigate the association between COPD
and IBD represented by CD and UC using the large data in Asia. We also aimed to
study the influence of COPD on the risk of IBD according to the severity of COPD.
Consideration  of  this  association  may  maximize  the  efficacy  of  prevention  and
treatment approaches to these chronic disease.
MATERIALS AND METHODS
Data source
This  nationwide,  population-based  study  was  conducted  using  data  from  the
National Health Insurance Service (NHIS) database. The South Korean government
administers  the  NHIS  as  a  mandatory  health  insurance  system  covering
approximately 97% of the South Korean population; the remaining 3% represent the
lower income population covered by the Medical Aid program. The NHIS database
provides  comprehensive  information  about  demographics,  medical  treatments,
procedures, outpatient and inpatient care, and disease diagnoses according to the
International Classification of Disease, 10th revision (ICD-10). In addition, in 2007, the
NHIS established a registration program for rare intractable disease (RID), which
included  IBD,  to  provide  enhanced  reimbursement  for  medical  costs  that  were
associated with rare diseases (affecting < 20000 people in Korea).  To qualify for
enrolment in the RID program, patients require a diagnosis from a certified physicians
and approval by the NHIS.
Study population and patient identification
We identified COPD patients based on the following diagnostic criterion: Conditions
for which an individual should visit the medical facility at least twice per year with
both a COPD diagnostic code and a prescription for one or more COPD medications
between  January  2010  and  December  2014.  Similar  to  previous  studies[20-22],  the
detailed diagnostic criteria of COPD are as follows: > 40 years of age; ICD-10 codes for
COPD (J43-J44, except J430); and use of more than one drug for COPD such as a long-
acting muscarinic antagonist (LAMA), long-acting beta-2 agonist (LABA), inhaled
corticosteroid (ICS),  ICS plus LABA, short-acting muscarinic antagonist (SAMA),
short-acting beta-2 agonist (SABA), SAMA plus SABA, methylxanthines, systemic
corticosteroids, and systemic beta agonists. Patients with COPD were divided into the
mild COPD group and severe COPD group and severe COPD was defined according
to  the  following severity  criteria:  (1)  Tertiary  hospital  care  patient  who met  the
definition of COPD described above; and (2) Use of triple inhaler therapy at least once
per  year  (ICS+LABA+LAMA).  In  addition,  patients  in  the  COPD  group  were
subsequently 1:5 matched with individuals without COPD (non-COPD controls) for
age and sex.
Incident cases of IBD were defined when the patients in the COPD group and non-
COPD  controls  met  the  case  definition  for  CD  or  UC  during  January  2010  and
December 2014 and had been free of IBD diagnosis for at least 2 years prior to the
beginning of the COPD case-defining period. We identified IBD patients using codes
from the ICD-10 and the RID registration system (V code). Cases that involved CD
were identified if they had both ICD-10 code K50 and V code V130, while cases that
involved UC were identified if they had both ICD-10 code K51 and V code V131. Since
IBD-unclassified is not registered in NHIS database and RID system as a definite
diagnostic code, it  was excluded from the analysis.  We defined the time point at
which this diagnosis was claimed using ICD-10 code and V code as “time 0” and
identified IBD patients.
For inclusion in the present study, patients had to fulfill the diagnostic criteria for
IBD, which were based on the clinical features, endoscopic findings, and histologic
findings that are required for registration in the RID program. Previous studies have
validated the accuracy of the RID database for both UC and CD diagnoses[14,23,24].
Statistical analysis
Statistical  analyses  were  performed  with  the  R  program,  version  3.4.3  (The  R
Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org)
and SAS,  version 9.2  (SAS Institute  Inc.,  Cary,  NC,  United States)  for  Windows.
Random selection of age- and sex-matched controls was performed using the SAS
algorithm. Data for continuous variables are presented as the mean and standard
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deviation[25].  Data  for  categorical  variables  are  presented  as  the  numbers  and
percentages. Differences in baseline characteristics and comorbidities between the
COPD group and non-COPD controls were analyzed with independent t-tests and χ2
tests, as appropriate. Incidence rates of IBD were calculated by dividing the number
of events by 1000000 person-years of follow-up for each group. Cox proportional
hazard regression models considering time-varying covariates were used to calculate
the hazard ratio (HR) and 95% confidence interval (CI) for the risk of IBD in patients
with  COPD  compared  to  controls[26].  The  cumulative  incidences  of  IBD  were
compared between the groups with the Kaplan-Meier method and the log-rank test. A
P value < 0.05 was considered statistically significant.
Ethical consideration
All data were obtained without identifiable information, such as the registration
number, patient’s name, or medical institution. This study’s protocol was approved
by the institutional review board of Seoul National University Hospital (H-1703-107-
840).  All  data  base  was encrypted and anonymous;  we did not  obtain  informed
consent from the study population.
RESULTS
Baseline characteristics of study population
A  total  of  1303021  patients  with  COPD  and  6515105  non-COPD  controls  were
included in this study. The mean age of the study population was 57.1 ± 10.7 years
and the mean duration of follow-up was 3.9 ± 1.4 years. The number of patients with
severe  COPD was  111459,  representing  8.6% of  all  COPD patients  and  1191562
patients (91.4%) had mild COPD. (Table 1) Compared to non-COPD controls, the
COPD  group  had  lower  proportions  of  urban.  However,  the  COPD  group  had
significantly higher proportions of individuals with the lower 20% incomes than non-
COPD controls. In the case of comorbidity, the COPD group had a higher prevalence
of diabetes mellitus, hypertension, and dyslipidemia.
Development of IBD in patients with chronic obstructive pulmonary disease
Comparison of  the incidence rate and risk of  IBD between patients with chronic
obstructive pulmonary disease and con-COPD controls is presented in Table 2. In the
COPD group, 513 patients (0.04%) developed IBD in the follow-up period, whereas
1,846  non-COPD controls  (0.03%)  developed IBD.  The  COPD group had higher
incidences of total IBD compared to non-COPD controls (Figure 1). The risk of IBD in
the COPD group was increased by 1.38 (adjusted HR; 95%CI: 1.25-1.52). Among the
513 patents with IBD in the COPD group, 406 were diagnosed with UC and 107 with
CD. The incidence rate of UC was higher in the COPD group than in the non-COPD
controls. CD also developed more frequently in the COPD group than in non-COPD
controls. There was an increased risk of developing both UC and CD in the COPD
group compared to in non-COPD controls.
Incidence  rates  and  relative  risks  of  IBD  according  to  chronic  obstructive
pulmonary disease severity
Table 3 reports the number of events, calculated incidence rates, and unadjusted and
adjusted HRs for IBD in the COPD group according to COPD severity. The incidence
rate of overall IBD was higher in the severe COPD group than in the mild COPD
group) (Figure 2). Both UC and CD were developed more frequently in the severe
COPD group than in the mild COPD group. The severity of COPD was associated
with an increased risk of  developing IBD. When IBD is  classified as UC and CD
separately, patients with severe COPD also had increased risk of developing UC and
CD compared to not only non-COPD controls but also the mild COPD group. This
tendency of  increased risk  of  IBD according  to  the  severity  of  COPD was  more
prominent in CD than in UC.
Subgroup analysis according to sex and age
For  the  subgroup  analysis,  of  the  entire  study  population  was  dichotomized
according to sex and age. The risk of IBD in the COPD group compared to the non-
COPD controls was analyzed according to sex and age (Table 4). Male patients with
COPD had increased risks of developing CD and UC compared to male patients
without COPD. This result was same for female patients with COPD. When the risk of
developing IBD was analyzed according to age, the risk of developing IBD in the
COPD group was higher than that in the non-COPD controls at all ages. In addition,
the risk of IBD increased with the severity of COPD irrespective of sex and age, and
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Table 1  Baseline characteristics of study population, n (%)
Non-COPD controls (n = 6515105) COPD group (n = 1303021) P value
Sex (Male %) 2867470 (44.0) 573494 (44.0) 1
Age (yr) 57.1 ± 10.72 57.1 ± 10.72 1
40-64 5025580 (77.1) 1005116 (77.1)
65- 1489525 (22.9) 297905 (22.9)
COPD severity
Mild 1191562 (91.4)
Severe 111459 (8.6)
Income Low1 1597508 (24.5) 357627 (27.5) < 0.001
Urban residents 2965581 (45.8) 567359 (44.1)
Comorbidity
Diabetes mellitus 640544 (9.8) 164860 (12.7) < 0.001
Hypertension 1703988 (26.2) 418880 (32.2) < 0.001
Dyslipidemia 1002279 (15.4) 272449 (20.9) < 0.001
Follow up duration (yr) 3.9 ± 1.4 3.9 ± 1.4 0.8803
1Denotes subjects with annual income lower than 20% among total population. COPD: Chronic obstructive pulmonary disease.
this tendency was more prominent in CD than in UC.
DISCUSSION
This is a large-scale and nationwide study to assess the risk IBD in COPD patients
compared to non-COPD controls. Several studies of regions with high incidence of
IBD such as Europe and Canada have reported similar findings[7-9]; however, this is
the  first  study  conducted  in  Asia  with  a  previously  low  prevalence  of  IBD.  In
addition, to our best knowledge, this is the first study that revealed a close association
between the severity of COPD and the risk of developing IBD.
We found that the incidence of IBD (UC and CD) in COPD patients was higher
compared to that in non-COPD controls. The higher risk of IBD in COPD patients
might be explained by the genetics, pathological background, and environmental
factors shared by these two disease. There are several reports investigating genes that
contribute to the development of both IBD and COPD. NOD2 is a cellular protein that
recognizes the bacterial muramyl dipeptide as a major component of the bacterial cell
wall. NOD2 mutations were significantly identified in patients with CD, and recent
studies have also reported this mutation in COPD patients[27].
The  Hedgehog-interacting  protein  gene  that  is  shown  to  be  a  potential  sus-
ceptibility locus for COPD is also important in the development of the intestinal crypt
axis and further studies are required to identify whether this gene contributes to the
disease overlap between COPD and IBD[28]. Dysregulation of protease activity also has
a role in both COPD and IBD. Increased levels of epithelial and leukocyte matrix
metalloproteinases, which have a role in the digestion of key components in mucosal
structural integrity have been associated with the pathogenesis of COPD and IBD[29-33].
Development  of  IBD  in  patients  with  COPD  can  also  be  explained  by  the
hypothesis  that  systemic  inflammation  is  caused  by  overspill  of  multiple
inflammatory mediators including C-reactive protein, IL-6, fibrinogen and activated
leucocytes resulting from lung inflammation[34]. Especially, several studies revealed
that plasma tumor necrosis factor (TNF-α) and its soluble receptor are increased in
patients with COPD than in healthy controls[35-37]. TNF-α is a pivotal cytokine in IBD
pathogenesis and IBD can be assumed to be one of the systemic inflammation caused
by COPD. However, despite this evidence and hypothesis, treatment with TNF-α
inhibitors have not shown significant benefit in patients with COPD[38].  This may
suggest that COPD is a highly complex inflammatory disease in which many other
cytokines  and  mediators  are  involved,  and  blocking  a  single  cytokine  does  not
necessarily lead to a clinically significant effect[39].
In addition, microbiomes common to the lung and gastrointestinal tract, as well as
autoimmune components of both diseases, can support the link between the two
diseases. We also demonstrated that the risk of developing UC and CD in COPD
patients  also  increased  with  the  severity  of  COPD and this  tendency  was  more
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Figure 1
Figure 1  The cumulative incidence of inflammatory bowel disease in chronic obstructive pulmonary disease
group and non-chronic obstructive pulmonary disease controls. IBD: Inflammatory bowel disease; COPD:
Chronic obstructive pulmonary disease.
pronounced in CD than in UC. This can be explained by understanding the effect of
hypoxia on IBD pathogenesis. The intestinal mucosal barrier is made up of epithelial
apical  junction complexes,  consisting of  tight junctions and adherence junctions,
which are sensitive to hypoxia. Severe hypoxemia caused by COPD is thought to
evoke diminished splanchnic perfusion and result in inadequate oxygen delivery to
the intestinal mucosal, causing tissue hypoxia, which is associated with increased
enterocyte damage and integrity loss[40,41]. In addition, mucosal barrier loss can be
accelerated by inflammatory mediators, which are known to circulate during COPD
aggravation as above mentioned[42]. For instance, cytokines can lead to alterations in
the  structure  of  tight  junctions,  thereby  resulting  in  enhanced  para-cellular
permeability and barrier loss[43]. The effects of hypoxia are expected to be more severe
as the severity of COPD increases, and a recent study showed an increased intestinal
permeability in patients undergoing acute exacerbations of COPD compared to the
same patients in a stable condition of COPD[44].
In this study, the number of IBD patients with UC was higher than those with CD
in the COPD group. This can be assumed to be due to the higher incidence of UC in
the entire IBD population in Korea compared to that of CD[16]. In addition, it may be
because of the nature of the disease that older patients are more likely to be present in
the COPD group. Approximately 10%-15% of IBD is diagnosed after the age of 60 and
older-onset UC is more common than CD[45-47].
Smoking is the most important risk factor for COPD, also affecting the pathogenesis
of  IBD,  protecting  against  UC,  and  promoting  the  development  of  CD [48,49].
Nevertheless, our study could not make adjustment for the smoking status due to lack
of information, and this is a weakness of this study. However, an analysis of the
database including the smoking status of the Korean population from the national
health screening program provided by the NHIS revealed that the proportion of ex-
and current smokers was significantly higher in the COPD group than in non-COPD
controls. (33.3% vs 31.1%, P < 0.001). And the proportion of IBD patients was also
higher in the COPD group than in non-COPD controls (0.04% vs 0.03%, P < 0.001)
(Supplementary material).
Our study could not  reflect  the actual  clinical  situation,  and this  is  one of  the
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Table 2  Incidence rate and risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease
Event DURATION (Person-years) Incidence rateof IBD Model 11 HR (95%CI) Model 22 HR (95%CI) P value
IBD
COPD No 1846 25697723.08 7.18 1 (Ref.) 1 (Ref.) < 0.001
Yes 513 5139283.39 9.98 1.39 (1.26-1.53) 1.379 (1.25-1.52)
UC
COPD No 1540 25697723.08 5.99 1 (Ref.) 1 (Ref.) < 0.001
Yes 406 5139283.39 7.9 1.32 (1.18-1.47) 1.315 (1.18-1.47)
CD
COPD No 306 25697723.08 1.19 1 (Ref.) 1 (Ref.) < 0.001
Yes 107 5139283.39 2.08 1.75 (1.40-2.171) 1.691 (1.35-2.10)
1Model 1: adjustment for age and sex;
2Model 2: adjustment for model 1+ place of resident, income, diabetes mellitus, hypertension, dyslipidemia. CD: Crohn’s disease; CI: Confidence interval;
COPD: Chronic obstructive pulmonary disease; HR: Hazard ratio; IBD: Inflammatory bowel disease; UC: Ulcerative colitis.
weaknesses  using  administrative  data.  This  limitation  is  associated  with  the
possibility  of  overlooking  the  risk  variables  that  are  important  for  disease
development. A well-designed prospective observational cohort study that combine
administrative data and actual clinical data including medications and other clinical
covariates is needed to reveal more precisely the association between COPD and IBD.
In conclusion, the incidences of both CD and UC were significantly increased in
COPD patients in South Korea and the risk of developing IBD also increased as the
severity  of  COPD  increased.  It  is  important  to  be  aware  of  the  gastrointestinal
symptoms indicative of IBD in COPD patients. Accurate clinical assessment should be
done, especially in patients with severe COPD in order to prevent complications and
avoid excess medical expenses.
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Table 3  Incidence and risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease according to disease
severity
Event DURATION (Person-years) Incidence rateof IBD Model 11 HR (95%CI) Model 22 HR (95%CI) P value
IBD
COPD Severity Non 1846 25697723.08 7.18 1 (Ref.) 1 (Ref.) < 0.001
Mild 461 4719752.21 9.77 1.36 (1.23-1.50) 1.35 (1.22-1.49)
Sev-
ere
52 419531.18 12.39 1.717 (1.29-2.24) 1.70 (1.27-2.21)
UC
COPD Severity Non 1540 25697723.08 5.99 1 (Ref.) 1 (Ref.) < 0.001
Mild 371 4719752.21 7.86 1.31 (1.17-1.47) 1.31 (1.17-1.47)
Sev-
ere
35 419531.18 8.34 1.39 (0.97-1.91) 1.38 (0.96-1.89)
CD
COPD Severity Non 306 25697723.08 1.19 1 (Ref.) 1 (Ref.) < 0.001
Mild 90 4719752.21 1.91 1.60 (1.26-2.02) 1.548 (1.22-1.95)
Sev-
ere
17 419531.18 4.05 3.38 (2.00-5.33) 3.29 (1.94-5.20)
1Model 1: adjustment for age and sex;
2Model 2: adjustment for model 1+ place of resident, income, diabetes mellitus, hypertension, dyslipidemia. CD: Crohn’s disease; CI: Confidence interval;
COPD: Chronic obstructive pulmonary disease; HR: Hazard ratio; IBD: Inflammatory bowel disease; UC: Ulcerative colitis.
Table 4  Risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease according to sex and age
COPD IBD UC CD
Male No 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 1.47 (1.23-1.60) 1.35 (1.16-1.55) 1.75 (1.26-2.39)
Female No 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 1.35 (1.16-1.55) 1.27 (1.07-1.5) 1.64 (1.20-2.21)
Age (40-64) No 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 1.36 (1.21-1.52) 1.31 (1.15-1.48) 1.62 (1.25-2.08)
Age (65-) No 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 1.46 (1.19-1.79) 1.36 (1.07-1.71) 1.93 (1.23-2.96)
CD: Crohn’s disease; COPD: Chronic obstructive pulmonary disease; IBD: Inflammatory bowel disease; UC: Ulcerative colitis.
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Figure 2
Figure 2  Comparison of cumulative incidence of inflammatory bowel disease in patients with chronic obstructive pulmonary disease according to the
severity of chronic obstructive pulmonary disease. IBD: Inflammatory bowel disease; COPD: Chronic obstructive pulmonary disease.
ARTICLE HIGHLIGHTS
Research background
Inflammatory bowel disease (IBD) is known to be associated with airway disease and there is a
growing evidence of increased risk of IBD among patients with chronic obstructive pulmonary
disease (COPD).
Research motivation
South Korea has a considerably high prevalence of COPD and is one of the highest incidence of
IBD among Asian countries. Previous western studies have reported the risk of IBD in COPD
patients, however, no research based on Asian data has been reported.
Research objectives
To estimate the incidence of IBD in patients with COPD compared to non-COPD controls and
the risk of IBD development according to COPD severity.
Research methods
From January 2010 and December 2014, patients with COPD were identified using International
Classification of Disease, 10th revision (ICD-10 code) and prescription records from the National
Health Insurance (NHI) database. The COPD patients were divided into the severe and the mild
COPD group. And these patients were subsequently 1:5 matches with individuals without
COPD. Newly diagnosed IBD patients with Crohn’s disease and ulcerative colitis were identified
using  ICD-10  code  and the  rare  intractable  disease  registration  program codes  from NHI
database.  The  risk  of  IBD  in  COPD  patients  compared  to  controls  was  analyzed  by  Cox
proportional  hazard regression  models.  The  cumulative  incidence  of  IBD were  compared
between the groups.
Research results
The COPD group had higher incidences of IBD compared to non-COPD controls and the risk of
IBD in the COPD group was increased. The incidence rate of IBD was higher in the severe COPD
group than in the mild COPD group.
Research conclusions
The incidences of IBD were significantly increased in COPD patients in South Korea and the risk
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of developing IBD also increased as the severity of COPD increased.
Research perspectives
Careful  monitoring  the  gastrointestinal  symptoms  indicative  of  IBD  in  COPD  patients  is
important. Accurate clinical assessment should be done, especially in patients with severe COPD
in order to determine the best strategies to prevent complications.
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